BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 14586548)

  • 1. Androgens and prostate cancer.
    So AI; Hurtado-Coll A; Gleave ME
    World J Urol; 2003 Nov; 21(5):325-37. PubMed ID: 14586548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of androgen-independent prostate cancer.
    Feldman BJ; Feldman D
    Nat Rev Cancer; 2001 Oct; 1(1):34-45. PubMed ID: 11900250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgens and androgen receptor in prostate cancer].
    Miyoshi Y; Kubota Y
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():489-93. PubMed ID: 16689355
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave ME; Zellweger T; Chi K; Miyake H; Kiyama S; July L; Leung S
    Invest New Drugs; 2002 May; 20(2):145-58. PubMed ID: 12099575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
    Griffiths K; Morton MS; Nicholson RI
    Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone dependency of prostate cancer].
    Suzuki H; Ito H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():59-64. PubMed ID: 12599546
    [No Abstract]   [Full Text] [Related]  

  • 8. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
    Gleave M; Nelson C; Chi K
    Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism on androgen-independent progression of prostate cancer].
    Shimazaki J; Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1997 May; 55(5):1143-8. PubMed ID: 9155166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor in prostate cancer.
    Heinlein CA; Chang C
    Endocr Rev; 2004 Apr; 25(2):276-308. PubMed ID: 15082523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of castration-recurrent prostate cancer.
    Azzouni F; Mohler J
    Urol Clin North Am; 2012 Nov; 39(4):435-52. PubMed ID: 23084522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.
    Bisoffi M; Klima I; Gresko E; Durfee PN; Hines WC; Griffith JK; Studer UE; Thalmann GN
    J Urol; 2004 Sep; 172(3):1145-50. PubMed ID: 15311059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.